CT38 acetate and proposed CRFR2 agonist uses — AU2022238570A1
Gerard Pereira · 2023 · AU2022238570A1 · patent family 83320930
Published 2023-09-28.
Reported patent results
Reported findings
The clinical example reproduces results from the 14-person InTiME pilot. A low-exposure subgroup of 10 averaged a 21.4% lower symptom score after infusion.
Example describes 14 recipients across four infusion-rate groups. This is the same small open-label study reported by Pereira and colleagues in 2021.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Symptom score below the 0.25 ng/mL exposure threshold | In the subgroup of 10, the 28-day mean fell from 29.1 to 22.9 (21.4%). | |
| Highest infusion rate | Both participants assigned the highest rate had higher symptom scores afterward. |
The example describes InTiME, which had no placebo arm.
Source for these results ↗ · Reviewed 2026-11-12
Patent claims and provenance
Use. The application claims controlled-release CRFR2 agonist uses including CT38 acetate, with ME/CFS and post-acute sequelae of SARS-CoV-2 among the proposed indications.
The human example reuses the InTiME pilot participants. It supplies no independent treatment cohort.
- Publication
- AU2022238570A1 ↗ · 2023-09-28
- Earliest priority / filing
- 2021-03-17 / 2022-03-17
- Original applicant / assignee
- Cortene Inc
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- 83320930 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Improved methods of treating diseases resulting from a maladapted stress response
Inventors: Gerard Pereira.
AU2022238570A1 · WO2022198230A1 · US20250319161A1 · EP4308150A1 · JP2024511066A · CA3212248A1
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The human example reuses the InTiME pilot participants. It supplies no independent treatment cohort.
- The example describes InTiME, which had no placebo arm.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Available format: Original patent text and indexed metadata
Material reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related publications may cover the same research program or participants.
Source access
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Source reviewed 2026-11-12.
Source type: Patent publication
Citation and original source
Original source: Gerard Pereira. CT38 acetate and proposed CRFR2 agonist uses — AU2022238570A1 AU2022238570A1 · patent family 83320930 2023.
Molekul research summary: https://molekul.io/research/patent-au2022238570a1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry